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Abstract
Highly selective, cell-permeable and fast-acting inhibitors of individual kinases are sought-after as tools for studying the
cellular function of kinases in real time. A combination of small molecule synthesis and protein mutagenesis, identified a
highly potent inhibitor (1-Isopropyl-3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine) of a rationally engineered Hog1
serine/threonine kinase (Hog1
T100G). This inhibitor has been successfully used to study various aspects of Hog1 signaling,
including a transient cell cycle arrest and gene expression changes mediated by Hog1 in response to stress. This study also
underscores that the general applicability of this approach depends, in part, on the selectivity of the designed the inhibitor
with respect to activity versus the engineered and wild type kinases. To explore this specificity in detail, we used a validated
chemogenetic assay to assess the effect of this inhibitor on all gene products in yeast in parallel. The results from this screen
emphasize the need for caution and for case-by-case assessment when using the Analog-Sensitive Kinase Allele technology
to assess the physiological roles of kinases.
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Introduction
Protein kinases have a crucial role in most, if not all, signaling
pathways and regulate diverse cellular functions, such as cell-cycle
progression, apoptosis, metabolism, differentiation, cell morphol-
ogy and migration, and secretion of cellular proteins [1]. Our
present understanding of the majority of cellular signal transduc-
tion takes the form of wiring diagrams in which many of the
component parts have been identified, and to some extent the
relative position of the components in a given pathway, but
beyond this static snapshot view, little is known about the details of
their dynamic operation. A critical piece of this puzzle is an
understanding of how external and internal inputs are sensed in a
time-dependent manner to effect a given signaling output. Highly
selective, cell-permeable and fast-acting inhibitors of individual
kinases would allow for the systematic investigation of the in vivo
cellular function of a kinase in real time. Protein kinases share
common sequences and structural homology in their ATP-binding
site. The fact that many kinases share a highly conserved catalytic
domain complicate the search for ATP competitive kinase
inhibitors with sufficient specificity [2]. However, this conserved
domain can be leveraged to deliver high selectivity by orthogonal
targeting [3]. This approach involves modifying a kinase inhibitor
to disrupt its binding affinity for its native target and subsequent
mutation of a protein to allow it to recognize the orthogonal
inhibitor. Shokat and colleagues have extensively used this
‘‘analog-sensitive’’ approach to study a range of protein kinases
[4]. Recently, this chemical genetic approach has been used to
identify four novel physiological substrates of Hog1 kinase [5], to
show that the catalytic activity of Hog1 prevents cross talk between
the high-osmolarity glycerol (HOG) pathway and both the
pheromone response and invasive growth pathways [6], as well
as to define the signaling properties underlying the HOG pathway
[7]. We wanted to explore orthogonal targeting in order to
develop selective and fast acting kinase inhibitors that would allow
us to study the dynamic behavior of kinases in the HOG pathway.
Herein we report the design, synthesis and evaluation of an
orthogonal inhibitor that is able to inhibit as kinases efficiently and
can be used to study signal transduction events that occur within
minutes, e.g. gene expression and cell cycle studies.
The HOG pathway of the yeast Saccharomyces cerevisiae is a
MAPK signaling pathway and is the functional homolog of the
stress activated MAPK JNK and MAPK p38 pathways of
mammals [8]. Because there is a high degree of conservation of
these cascades, the yeast HOG pathway is a good model to study
osmotic adaptation processes. The HOG pathway consists of two
upstream osmosensing branches, the Sln1 and Sho1 branches, and
a downstream MAP kinase cascade including the Ssk2/22, Ste11
MAP3K, the Pbs2 MAPKK and Hog1 MAPK [9]. Activation of
the Hog1 MAPK elicits an extensive program required for cell
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Specifically, Hog1 regulates gene expression by activation of
specific transcription factors but also through chromatin binding,
Hog1 recruits chromatin modifying/remodeling activities to stress-
responsive genes altering their expression [8,10]. In addition,
environmental stressors (e.g. changes in osmolarity) critically affect
progression through the cell cycle [9,11,12].
To develop an analog-sensitive inhibitor of an engineered Hog1
kinase, we selected the pyrazolopyrimidines as they represent an
excellent scaffold for targeting the protein kinase family due to
their structural similarity to the adenine moiety of ATP,
furthermore, the scaffold has been shown to have activity against
multiple kinase subfamilies. For example, different chemical
substitutions around this scaffold result in increased selectivity in
the inhibition of KDR [13], Src [14], and EGF [15] kinase
families. Furthermore, this scaffold has previously been used to
make orthogonal inhibitors [16]. We present here the design and
synthesis of a novel orthogonal inhibitor based on the pyrazolo-
pyrimidine that effectively inhibits a Hog1as kinase, and is able to
dissect the transient cell cycle arrest and regulation of gene
expression mediated by Hog1 in response to stress.
Results and Discussion
Because of its central role in cellular homeostasis and the
implication of human homologs in diverse disease states, we
selected Hog1 as the target of our mutant kinase-inhibitor pair
design. Sequence alignment analyses identified the conserved
T100 as a gatekeeper residue in Hog1 [5,6]. Visual inspection of
the binding pocket of an initial homology model of Hog1, using
the structure of human p38 in the absence of a ligand (pdb code
1p38) for a template, indicated that a narrow path leads to a
buried cavity within the ATP binding domain (Figure 1).
The cavity size and shape is comparable to that of a phenyl
group, and mutation of T100 for a glycine would widen the pocket
further (Figure 1). We therefore sought a compound that was
based on the pyrazolopyrimidine structure, having a phenyl ring
attached to it via a spacer of the appropriate length. Candidate
compounds were manually docked into the binding site and the
geometries were optimized in torsion space using an all-atom
representation of both ligand and receptor, keeping the receptor
fixed. 1-NM-PP1, a commercially available ATP competitive as-
inhibitor was compatible with our model, but did not fit as well as
other compounds into the ATP binding site of Hog1as. The
resulting model complex that best matched our specifications
included a two-carbon, triple-bonded linker (compounds with the
general structure 6, Figure 1). The triple bound would place the
benzene ring in such orientation that it fills up the lipophilic pocket
that becomes accessible upon mutation. At the same time, the
heterocyclic moiety can make similar interactions with the hinge
area as would ATP. In the wild-type kinase the non-mutated
gatekeeper residue should block access to the lipophilic pocket
(indicated in red).
Previous published synthetic approaches for making 1,3-
disubstituted pyrazolopyrimidines involves at least five sequential
reaction steps, but more importantly, the R1 substituent is
introduced in the first step [17,18]. Therefore, the generation of
analogues with varying C3 substituents is inefficient. We devised a
convergent route for making 1,3-disubstituted pyrazolopyrimi-
dines. This route involves the synthesis of a common intermediate,
4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidine (3) that allows rap-
id derivatization of the heterocyclic core scaffold in two steps
(Figure 2).
The common intermediate, 4-amino-pyrazolopyrimidine (2),
was synthesized from (1) by a 4-step synthesis, on a multigram
scale in 64% overall yield without the use of any chromatography.
The corresponding 4-amino-3-iodopyrazolopyrimidine (3) was
synthesized using N-iodosuccinimide (Figure 2) [19].
Starting from compound 3, a two-step derivatization process
was developed. Initially, we found that alkylation of the N1 with 2-
Figure 1. Inhibitor docked to Hog1. Compound 6a docked to the
homology models of wild-type (red mesh) and T100G mutant (ball-and-
stick and yellow surface) Hog1, shown as cross sections from two
angles, rotated 90 degrees around the horizontal axis. Compound 6a
was designed to occupy the region available only for the T100G mutant
(red mesh near phenyl ring) for specificity.
doi:10.1371/journal.pone.0020789.g001
Figure 2. Synthesis of 1,3-disubstituted pyrazolopyrimidines.
doi:10.1371/journal.pone.0020789.g002
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yield (58%). Treatment of 3 with 1.1 equiv of 2-chloropropan and
1.2 equiv of NaH in DMF for 3 h at 100uC gave a mixture of the
N1 and N4 alkylated products. However, when the base was
exchanged with K2CO3 and the reaction was carried out with
microwave assisted heating at 200uC for 5 min, high region-
selectivity was achieved and 4a was obtained in nearly
quantitative yield. Using the same reaction conditions in
combination with commercial available 2-(2-Chloroethoxy)tetra-
hydro-2H-pyran or 4-Chloromethyl-2,2-dimethyl-1,3-dioxolane
compounds 4b and 4c were obtained in 70% and 79% yield
respectively.
Compound 4 was then reacted with 4-halogenphenyl boronic
acid (1.3 eq) Pd(PPh3)2Cl2, (3 mol %), 2M aq. K2CO3 (10 eq) in
THF at reflux for 16 h to generate compounds with the general
structure 5 [17] or with 1-ethenyl-4-halobenzene, Pd(PPh3)2Cl2,
(3 mol %), Et3N (2 eq) and CuI (6 mol %) in THF at reflux for
16 h to generate compounds with the general structure 6 [20]. In
all cases the reactions proceeded with high turnover of the starting
material and the target compounds were obtained in high yields
(75–90%). Removal of the acid labile protection groups in 6d and
6e were carried out with 2N HCl in THF, resulting in compound
7a and 7b in 92% and 90% isolated yield respectively.
Using standard methods, we cloned, expressed and purified the
glutathione-S-transferase (GST) fusion proteins of Hog1wt and
Pbs2wt as well as the mutated kinases (Hog1as and Pbs2as). The
analogue sensitive mutant allele of each kinase (as mutant) was
created by the replacement of a conserved bulky residue with a
glycine (T100G) in Hog1 or an alanine (M435A) in the active site
of Pbs2.
Based on the analyses of their in vitro kinase activity, both
Hog1as and Pbs2as were more active when the phosphodonor is
the analogue Phenyl-Ethyl-ATP (PE-ATP) versus ATP, consistent
with previous reports [5]. It is worth noting that, Hog1 expressed
from E. coli was not inhibited by 1-NM-PP1 (9, Figure 3)
[16,21,22,23], while Hog1 produced from yeast was sensitive to
this inhibitor (data not shown). This observation suggests the E.
coli protein is inactive/only partially active and that full function
of Hog1 depends on association with another yeast protein, such
as a chaperone or that the conformation or postranslational
modification of the Hog1 protein in E. coli is different from that
produced in yeast.
We tested the 1,3-disubstituted pyrazolopyrimidines (6a–6c,
5a, 5b), as well as SB203580 (8, a known inhibitor of p38a, p38b
and AKT/PKB. p38 is the mammalian homologue of Hog1) and
1-NM-PP1 (9, Figure 3). Hog1as was totally inhibited in vitro by 8
and 9, and almost totally inhibited (.89%) by 6a–6c, with the two
last (5a and 5b) the least efficient. Pbs2as was inhibited by all the
compounds in vitro, but not as efficient as for Hog1 as. Protein
levels were similar in all assays based on inspection of coomassie
stained gels. As expected (as it is its homologue p38 in mammals),
Hog1wt was inhibited by 8, and poorly (range 8–25%) inhibited
by the rest of compounds except for 5b (94%). Finally, none of the
inhibitors had an effect on Pbs2wt.
The in vitro IC50 values for compounds 9 and 6a that target
Hog1as and Pbs2as were determined (Figure 3F). Compound 9
was 4-times more efficient than 6a when targeting Hog1as, while
6a is less than two times more efficient when 9 when targeting
Pbs2as. Thus, both inhibitors inhibited the kinases in vitro at a
similar range of concentrations.
As the mutated proteins were functional in vitro, yeast strains
expressing the modified kinases were generated. Once we had
checked that hog1as or pbs2as strains were osmoresistant (data not
shown), we followed the transcriptional response to osmostress
Figure 3. In vitro inhibition of Hog1 and Pbs2. In vitro inhibition
of Hog1as (B) and Pbs2as (D) mutant variants by inhibitors, and effect in
the wild type partners (A and C). The inhibitors used [final concentration
5 mM] were 6a–6c, 5a, 5b, as well as SB203580 (8) (a known inhibitor of
p38a, p38b, p38b2 and AKT/PKB) and 1NMPP1 (9), a known inhibitor of
the as kinases. Recombinant, tagged proteins were purified either from
S. cerevisiae (Hog1) or E.coli ( P b s 2 )a n dw e r ea s s a y e df o rt h e
phosphorylation of Sic1 (substrate of Hog1) or Hog1 (as substrate of
Pbs2). Phosphorylated proteins were resolved by SDS-PAGE and their
phospho-state detected by autoradiography. IC50 values for in vitro
inhibition of Hog1as and Pbs2as mutant variants by 6a and 9 (F).
Recombinant tagged proteins were purified either from S. cerevisiae
(Hog1) or E.coli (Pbs2) and were assayed for phosphorylation of Sic1
(substrate of Hog1) or Hog1 (as substrate of Pbs2). The results are the
means 6 S.D. of at least three independent experiments.
doi:10.1371/journal.pone.0020789.g003
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with the different inhibitors for 8 hours at a fixed concentration of
5 mM, before an osmotic shock with 0.4 M NaCl. The results
agreed with those observed in the in vitro assay, with the exception
of 8, that was less effective in vivo.
To further characterize 6a we performed a time course at a
concentration of 2 mM (end-point analysis), a concentration that
does not manifest a fitness defect in a HOG1 strain, but is sufficient
to almost totally inhibit Hog1as (Figure 5 and data not shown). At
5 minutes of incubation with 6a the b-galactosidase activity was
inhibit by 86%, with an IC50 of 238 nM (Figure 5A and 5C). This
rapid inhibition of gene expression by 6a suggests that this
compound could be a key, fast-acting tool to study some of the
aspects of the mRNA biogenesis regulated specifically by the Hog1
MAPK as by signaling kinases in general.
To complement the end-point analyses of the inhibitors effect
on transcription we also carried out a time course experiment for
both hog1as and pbs2as (Figure 6). The addition of 6a five minutes
before stress completely blocked the expression of STL1, which in
the absence of the inhibitor, increased up to 30 minutes in
response to osmostress. Similar results were obtained by inhibition
of Hog1as and Pbs2as.
To analyze whether the solubility of the molecule could affect
the inhibition by 6a, we tested two derivatives with one or two
hydroxyl functions (7a and 7b). We reasoned that increased
solubility could result in better uptake and therefore more potent
compounds. On the other hand, too polar compounds could be
less bioactive if they are unable to cross the lipophilic cell
membrane. However, we did not observe either a faster uptake or
a faster inhibition with these two new derivates (Figure 7). Thus,
although in vitro these compounds were able to inhibit Hog1as as
efficiently as 6a (Figure 7A), they did not improve the inhibition of
the MAPK in vivo (Figure 7B).
The Stress-Activated Protein Kinase (SAPK) Hog1 elicits a
program for cell adaptation that includes the control of gene
expression and the modulation of cell-cycle progression. As recent
studies have shown that monitoring SAPKs activity in vivo by
reversable inhibition, we wanted to know if 6a, is a suitable tool to
study the transient cell cycle arrest mediated by Hog1 activation in
response to stress.
Figure 4. Transcription is inhibited by novel ATP analogues in
response to stress. hog1as or pbs2as yeast cells were transformed
with a STL1::LacZ reporter construct. Cells were grown to an OD660 of
0.2, incubated with the inhibitors for 8 hours at a concentration of
5 mM, and b-galactosidase activity was assayed before (2NaCl) or after
(+NaCl) osmotic stress (0.4 M NaCl for 30 min). b-galactosidase activity
is presented in nanomols per minute per milligram. Data represent the
mean of at least three independent experiments.
doi:10.1371/journal.pone.0020789.g004
Figure 5. 6a is efficient shortly after incubation. Time course at
2 mM concentration of (A) 6a in the hog1as strain. hog1as cells
transformed with the STL1::LacZ reporter were incubated with 2 mMo f
each inhibitor, subjected to osmotic stress (0.4 M NaCl), and cells were
collected at different times. b-galactosidase activity is presented as fold
induction of control versus NaCl-treated cells. (B) Dose response curve
at 5 minutes of incubation with 6a. hog1as cells were treated with
different concentrations of 6a for 5 minutes, subjected to osmotic
shock and b-galactosidase activity was assayed as described above
activity given in nanomols per minute per milligram). Efficiency of in
vivo inhibition of hog1as and pbs2as strains by 6a (C). hog1as STL1::LacZ
or Pbs2as STL1::LacZ yeast cells were incubated with the inhibitors for
5 minutes, and b-galactosidase activity was assayed before (2NaCl) or
after (+NaCl) osmostress (0.4 M NaCl for 30 min). Data6s.d. from at
least three independent experiments are shown.
doi:10.1371/journal.pone.0020789.g005
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in activation of Hog1. It is known that cells manifest a transient
cell cycle arrest in response to Sln1 inactivation, a phenotype that
can be followed by flow cytometry [12,24]. A temperature
sensitive allele of SLN1,( sln1
ts4) arrests at G1 phase following
synchronization at G1/S with mating pheromone and release into
the restrictive temperature (Figure 8, lane A). This arrest can be
circumvented by mutations on the HOG1 gene (in hog1 cells) or if
cells are pre-incubated with 6a for as little as 10 min.
Our results demonstrate that 6a is a powerful tool to study
transient cell cycle arrest or gene expression mediated by Hog1 in
response to stress. In addition, 6a was recently used to demonstrate
that dynamic signaling in the Hog1 pathway relies on high basal
signal transduction [7]. However, the general applicability of this
approach depends, in part, on the selectivity with 6a inhibit the
mutant protein kinases compared with the other wild-type protein
kinases that are expressed endogenously in the same cells [25]. We
therefore examined the specificity of 6a by chemical genetic
profiling of the yeast deletion mutant collection and scored for
mutants with reduced growth in the presence of 500 mM 6a and
without osmotic stress (Figure 9). It should be noted that the
concentration of 6a used in this experiment was 100 times higher
than what was required to get efficient inhibition of Hog1as (5 mM)
in osmotic stressed cells and only off-target effects as well as
secondary effects of these was expected to be identified. This
analysis revealed that 60 strains that showed a significant depletion
from the pool of 1200 essential heterozygotes and 4800 non-
essential homozygous diploids (i.e. with a log2 ratio greater than 1)
when cultured competitively in the presence of 500 mM 6a.
Notably, of the 60 gene deletion strains (see table S1, Supporting
Information), 50 could be classified into five functional groups;
kinases (6), other enzymes 14), cytoskeleton (17), transcription
regulation (10), and cell wall (3), clearly demonstrating that several
off-target effects takes place at this concentration of 6a. A similar
experiment has been reported using compound 9 (500 nM)
targeting cdc28-as, showing excellent selectivity for the targeted
kinase [26]. However, when the inhibitor concentration was
increased to 5 mM several strains came up as sensitive, with several
of these having a catalytic/nucleoside triphosphate binding role.
Our results are consistent with these data. Together, these results
Figure 6. Inhibition over stress time course. hog1as STL1::LacZ (A)
and pbs2as STL1::LacZ (B) cells were incubated with 5 mMo f6a for
5 minutes and then, subjected to osmostress (0.4 M NaCl). Cells were
collected at the indicated times. b-galactosidase activity is given as % of
fold induction of control versus NaCl-treated cells. Data6s.d. from three
independent experiments are shown.
doi:10.1371/journal.pone.0020789.g006
Figure 7. Hydroxylated derivates of 6a. (A) To increase the
solubility of 6a two derivatives 7a and 7b were synthesized. In vitro-
activated Hog1 as was inhibited 7a and 7b.( B )hog1as cells
transformed with the STL1:LacZ reporter were pre-incubated with
2 mMo f7a and 7b for the indicated times. Cells were subjected to
osmotic stress (0.4 M NaCl) for 30 minutes and gene expression
measured as before. b-galactosidase activity is given as fold induction
of control versus NaCl-treated cells (activity given in nanomols per
minute per milligram). Data6SD. from three independent experiments
are shown.
doi:10.1371/journal.pone.0020789.g007
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understanding the specific activity of each particular inhibitor.
To summarize, a potent, cell-permeable as-inhibitor of the yeast
Hog1 MAP kinase has been developed and its utility has been
demonstrated by studying various roles of the Hog1 kinase. The
inhibitor can be regarded as a ‘‘sister-compound’’ of the
commercial 1-NM-PP1. The inhibitor will be a very useful tool




13C NMR spectra were obtained from a JEOL JNM-
EX 400 spectrometer. Column chromatography was performed
on wet packed silica (0.040–0.063 mm) using flash chromatogra-
phy. Microwave reactions were performed in a Biotage Initiator
reactor with fixed hold time. Amino-3-iodo-1H-pyrazolo[3,4-
d]pyrimidine was prepared following a literature procedure [19].
1H-pyrazolo[3,4-d]pyrimidin-4-amine (2). A solution of
malononitrile (22.6 g, 0.344 mol), triethyl orthoformate (83 mL,
0.499 mol), and acetic anhydride (77 mL, 0.791 mol) was heated
to 100uC for 5 h. After cooling to rt the solution was concentrated
on the rotary evaporator. The solution was left to crystallize at rt
overnight and the yellow solid was recrystallized from EtOH to
give 36.0 g (98.5%) of 1,1-dicyano-2-ethoxylethene as yellow
crystals. This material (36.0 g, 0.339 mol) was added carefully and
in small portions to cold (0uC) hydrazine hydrate (99.5%, 26 g,
0.807 mol). The solution was heated to reflux for 1 h and then left
to cool at rt whereupon the contents of the flask solidified. Water
(25 mL) was added to the solid material and the mixture was left in
the refrigerator overnight. The mixture was filtered and the solid
was washed with 10 mL of cold water and suction dried for about
5 minutes. The product was dried in a vacuum desiccator over
calcium chloride and was obtained in 75.5% (27.7 g). This
material (27.6 g, 0.255 mol) was added to formamide (42 mL).
The solution was vigorously boiled for 30 minutes (216uC oil
bath). The creamy suspension was left to cool at rt, diluted with
water (70 mL), and filtered. The light tan colored solid was washed
with water, suction dried, and dried in a vacuum desiccator over
calcium chloride to give the target compound in 86% yield (29.6 g)
that gives an overall yield of 64% (calculated over three steps).
NMR was in agreement with published data [27].
General procedure A; alkylation of N-1. Compound 3 (1
eq) and K2CO3 (2 eq) were suspended in 12 ml of dry DMF in a
20 ml microwave vessel. To this mixture, R1-Cl (1.1 eq) was added
and the sealed tube was heated to 200uC for 5 min. (20 s of pre-
stirring and fixed hold time: on). After cooling of the reaction
mixture to room temperature, additional R1-Cl (0.5 eq) was added
and the microwave vessel was heated again to 200uC for 5 min.
After cooling to ambient temperature, the reaction mixture was
diluted with DMF and filtered. The solvent was removed in vacuo
at 80uC and the residue was co-distilled with toluene three times.
The crude product was purified by flash column chromatography
on silica gel.
3-Iodo-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(4a). Compound 3 (2.00 g, 7.66 mmol) was converted to the
target compound using general procedure A. The crude product
was purified by flash column chromatography on silica gel
(MeOH:CHCl3=1:20) to give 97% (2.25 g) of 4a as fine yellow
needles.
1H NMR (400 MHz, CDCl3) d 1.55 ppm (d, 6H), 5.09
(m, 1H), 6.17 (bs, 2H), 8.32 (s, 1H).
13C NMR (100 MHz, CDCl3)
d 22.27 ppm, 49.89, 85.62, 104.25, 153.17, 155.88, 157.63. Anal.
Calcd for C8H10IN5 (303.00): C, 31.70; H, 3.33; N, 23.11. Found:
C, 31.84; H, 3.40; N, 23.19.
3-Iodo-1-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyra-
fzolo[3,4-d]pyrimidin-4-amine (4b). Compound 3 (2.00 g,
7.66 mmol) was converted to the target compound using general
procedure A. The crude product was purified by flash column
chromatography on silica gel (MeOH:CHCl3=1:20) to give 70%
(2.09 g) of 4b as a yellow powder.
1H NMR (400 MHz, CDCl3) d
1.27–1.64 ppm (m, 6H), 3.30–3.39 (m, 1H), 3.48–3.58 (m, 1H),
3.77–3.86 (m, 1H), 3.99–4.09 (m, 1H), 4.42–4.59 (m, 3H), 8.22 (s,
1H).
13C NMR (100 MHz, CDCl3) d 18.93 ppm, 25.30, 30.21,
47.26, 61.71, 64.85, 86.59, 98.12, 103.77, 154.14, 155.79, 157.89.
Anal. Calcd for C12H16IN5O2 (389.03): C, 37.03; H, 4.14; N,
17.99. Found: C, 37.04; H, 4.15; N, 18.04.
1-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)-3-iodo-1H-py-
razolo[3,4-d]pyrimidin-4-amine (4c). Compound 3 (2.00 g,
Figure 8. 6a is a suitable tool to study the transient cell cycle
arrest mediated by Hog1. The sln1
ts4 hog1as or hog1as strains were
synchronized with a-factor for 1 h, incubated with 5 mMo f6a for
10 minutes (B), shifted to 37uC for 10 minutes and then released into
YPD medium at 37uC plus the inhibitor (time 0). Total DNA content was
assessed by flow cytometry and presented as cell counts (y-axis) versus
1C and 2C DNA content (x-axis).
doi:10.1371/journal.pone.0020789.g008
An Inhibitor for Analog-Sensitive (as) Kinases
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procedure A. The crude product was purified by flash column
chromatography on silica gel (MeOH:CHCl3=1:20) to give 73%
(2.09 g) of 4c as fine yellow needles.
1H NMR (400 MHz,
CDCl3) d 1.33 ppm (d, 6H), 1.40 (s, 3H), 3.92–3.96 (m, 1H),
4.04–4.08 (m, 1H), 4.56–4.65 (m, 2H), 6.24 (bs, 2H), 8.34 (s, 1H).
13C NMR (100 MHz, CDCl3) d 25.52 ppm, 27.00, 50.12, 67.34,
74.28, 86.91, 104.17, 110.17, 154.59, 156.45, 157.69. Anal.
Calcd for C11H14IN5O2 (375.02): C, 35.22; H, 3.76; N, 18.67.
Found: C, 35.24; H, 3.79; N, 18.65.
General procedure B; Suzuki couplings. Compound 4 (1
eq), Ar-B(OH)2 (1.3 eq) and Pd(PPh3)2Cl2 (3 mol %) were
suspended in DMF (2 ml) and 2 M aq K2CO3 added. The
reaction vial was sealed and heated in a microwave reactor to
140uC for 10 min. After cooling to ambient temperature, the
reaction mixture was diluted with DMF and filtered. The solvent
was removed in vacuo and the residue was co-distilled with toluene
three times. The crude product was purified by flash column
chromatography on silica gel.
3-(4-Chlorophenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyri-
midin-4-amine (5a). Compound 4a (2.00 g, 6.60 mmol) was
converted to the target compound using general procedure B.
The crude product was purified by flash column chrom-
atography on silica gel (MeOH:CHCl3=1:35) to give 70%
(1.33 g) of 5a as fine yellow needles.
1H NMR (400 MHz,
CDCl3) d 1.59 ppm (d, 6H), 5.18 (m, 1H,), 6.17 (bs, 2H), 7.48–
7 . 5 4( m ,2 H ) ,7 . 6 3 – 7 . 6 8( m ,2 H ) ,8 . 3 5( s ,1 H ) .
13C NMR
(100 MHz, CDCl3) d 22.19 ppm, 46.16, 98.71, 129.70, 130.03,
135.28, 142.78, 173.77, 155.62, 158.10. Anal. Calcd for
C14H14ClN5 (287.75): C, 58.44; H, 4.90; N, 24.34. Found: C,
58.46; H, 4.91; N, 24.36.
3-(4-Fluorophenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyri-
midin-4-amine (5b). Compound 4a (2.00 g, 6.60 mmol)
was converted to the target compound using general procedure
A. The crude product was purified by flash column chrom-
atography on silica gel (MeOH:CHCl3=1:35) to give 79%
(1.41 g) of 5b as fine yellow needles.
1HN M R( 4 0 0M H z ,
CDCl3) d 1.58 ppm (d, 6H), 5.16 (m, 1H,), 6.19 (bs, 2H), 7.18–
7.24 (m, 2H), 7.66–7.71 (m, 2H), 8.32 (s, 1H).
13CN M R
(100 MHz, CDCl3) d 22.06 ppm, 48.96, 98.58, 116.42, 129.77,
130.46, 142.89, 153.52, 155.41, 158.16, 163.24. Anal. Calcd
for C14H14FN5 (271.30): C, 61.98; H, 5.20; N, 25.81. Found:
C, 61.99; H, 5.22; N, 25.84.
General procedure C; Sonogashira couplings. Com-
pound 4a (1 eq), Ar-CCH (1.3 eq), Pd(PPh3)2Cl2 (3 mol %)
Et3N (2 eq) and CuI (6 mol %) in THF was refluxed for 16 h.
After cooling to ambient temperature, the reaction mixture was
filtered. The solvent was removed in vacuo and the residue was co-
distilled with toluene three times. The crude product was purified
by flash column chromatography on silica gel.
1-Isopropyl-3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyri-
midin-4-amine (6a). Compound 4a ( 0 . 2 0g , 0 . 6 6m m o l )
was converted to the target compound using general procedure
C. The crude product was purified by flash column
chromatography on silica gel (MeOH:CHCl3=1:30) to give
81% yield (148 mg) of 6a as fine white powder.
1HN M R
(400 MHz, CDCl3) d 1.55 ppm (d, 6H), 5.09 (m, 1H), 6.17 (bs,
2H), 8.32 (s, 1H).
13C NMR (100 MHz, CDCl3) d 22.27 ppm,
49.89, 85.62, 104.25, 153.17, 155.88, 157.63. Anal. Calcd for
C16H15N5 (277.13): C, 69.29; H, 5.45; N, 25.25. Found: C,
69.35; H, 5.46; N, 25.21.
3-((4-fluorophenyl)ethynyl)-1-isopropyl-1H-pyrazolo[3,4-
d]pyrimidin-4-amine (6b). Compound 4a (0.20 g, 0.66mmol)
was converted to the target compound using general procedure C.
The crude product was purified by flash column chromatography
on silica gel (MeOH:CHCl3=1:30) to give 79% yield (154 mg) of
6b as fine white powder.
1H NMR (400 MHz, CDCl3) d 1.58 ppm
(d, 6H), 5.16 (m, 1H), 6.22 (bs, 2H), 7.07–7.11 (m, 2H), 7.56–7.60
(m, 2H), 8.36 (s, 1H).
13C NMR (100 MHz, CDCl3) d 22.20 ppm,
49.67, 80.97, 92.91, 102.07, 116.23, 117.92, 125.92, 134.04,
152.71, 156.37, 158.02, 163.32. Anal. Calcd for C16H14FN5
(295.30): C, 65.07; H, 4.78; N, 23.71. Found: C, 65.10; H, 4.73;
N, 23.77.
3-((4-chlorophenyl)ethynyl)-1-isopropyl-1H-pyrazolo[3,4-
d]pyrimidin-4-amine (6c). Compound 4a (0.20 g, 0.66
mmol) was converted to the target compound using general
procedure C. The crude product was purified by flash column
chromatography on silica gel (MeOH:CHCl3=1:30) to give 87%
yield (179 mg) of 6c as a white powder.
1H NMR (400 MHz,
CDCl3) d 1.46 ppm (d, 6H), 5.04 (m, 1H), 7.54 (d, 2H), 7.78 (d,
2H), 8.25 (s, 1H).
13C NMR (100 MHz, CDCl3) d 21.71 ppm,
48.76, 82.22, 91.69, 120.34, 124.77, 128.77, 133.61, 134.11,
152.28, 156.21, 157.71. Anal. Calcd for C16H14ClN5 (311.09): C,
61.64; H, 4.53; N, 22.46. Found: C, 22.46; H, 4.53; N, 22.42.
3-(Phenylethynyl)-1-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-
1H-pyrazolo[3,4-d]pyrimidin-4-amine (6d). Compound 4b
(0.20 g, 0.66 mmol) was converted to the target compound using
general procedure C. The crude product was purified by flash
column chromatography on silica gel (MeOH:CHCl3=1:30) to give
81% yield (194 mg) of 6d as a slightly yellow powder.
1HN M R
(400 MHz, CDCl3) d 1.38–1.75 ppm (d, 6H), 3.41–3.52 (m, 1H),
3.62–3.70 (m, 1H) 3.91–3.99 (m, 1H), 4.14–4.22 (m, 1H), 4.56–4.71
(m, 3H), 5.93 (bs, 2H), 7.38–7.47 (m, 3H), 7.58–7.63 (m, 2H), 8.40 (s,
1H).
13C NMR (100 MHz, CDCl3) d 19.10 ppm, 25.48, 30.42.
47.47, 61.94, 65.00, 80.93, 94.26, 98.40, 101.85, 121.67, 126, 74,
128.78, 129.64, 131.94, 154.04, 156.60, 158.10. Anal. Calcd for
C20H21N5O2 (363.17): C, 66.10; H, 5.82; N, 19.27. Found: C, 66.12;
H, 5.83; N, 19.30.
1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-3-(phenylethy-
nyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (6e). Com-
pound 4c (0.20 g, 0.66 mmol) was converted to the target
compound using general procedure C. The crude product was
purified by flash column chromatography on silica gel
(MeOH:CHCl3=1:20) to give 83% yield (191 mg) of 6e as a
white powder.
1H NMR (400 MHz, CDCl3) d 1.34 ppm (d,
3H), 1.40 (s, 3H), 3.94–4.00 (m, 1H), 4.06–4.11 (m, 1H) 4.43–
4.52 (m, 1H), 4.58–4.69 (m, 2H), 6.20 (bs, 2H), 7.37–7.46 (m,
3H), 7.57–7.62 (m, 2H), 8.39 (s, 1H).
13C NMR (100 MHz,
CDCl3) d 25.52 ppm, 27.01, 50,09, 67.42, 74.25, 80.80, 94.56,
101.90, 110.18, 121.60, 127.14, 128.85, 129.78, 132.01,
154.12, 156.93, 157.99. Anal. Calcd for C19H19N5O2
(349.15): C, 65.32; H, 5.48; N, 20.04. Found: C, 65.35; H,
5.50; N, 20.09.
General procedure D; deprotection of acid labile
groups. The starting material (1 eq) was dissolved in 9 ml
THF and 6 ml of 2N HCl was added. The mixture was stirred at
Figure 9. Chemical genetic profiling validation. (A) Visualization of genes sensitive to 500 mM 6a. The fold change (log2(6a-treated/untreated))
in microarray signal intensity is plotted on the y-axis for ,6000 genes (arranged alphabetically on the x-axis). (B) A network showing Kegg Pathways
(Blue nodes) and related GO Terms (Red nodes) that are significantly enriched (FDR q-value ,0.15) in the genes that are sensitive to the compound in
the chemogenomic profile. Nodes are connected based on mutual overlap. Node size is proportional to the total number of genes in each set and
edge thickness represents the number of overlapping genes between sets.
doi:10.1371/journal.pone.0020789.g009
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evaporated with toluene three times. The product was purified by
crystallization from MeOH/Et2O.
2-(4-amino-3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimi-
din-1-yl)etanol (7a). Compound 6d (0.15 g, 0.48 mmol) was
converted to the target compound using general procedure C
and was obtained in 92% yield (120 mg) of 7a as a white
powder.
1H NMR (400 MHz, DMSO) d 3.84 ppm (t, 2H), 4.22
(t, 2H), 7.45–7.54 (m, 3H), 7.73–7.79 (m, 2H), 8.49 (s, 1H).
13C
NMR (100 MHz, DMSO) d 50.18 ppm, 59.01, 79.72, 94.50,
99.93, 120.98, 127.37, 128.68, 129.79, 132.06, 150.22, 151.82,
153.51. Anal. Calcd for C15H14ClN5O (315.09): C, 57.05; H,
4.47; N, 22.18. Found: C, 57.10; H, 4.51; N, 22.24.
3-(4-amino-3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrim-
idin-1-yl)propane-1,2-diol (7b). Compound 6d (0.15 g,
0.43 mmol) was converted to the target compound using
general procedure C and was ob t a i n e di n9 0 %y i e l d( 1 3 3m g )
of 7b as a white powder.
1H NMR (400 MHz, DMSO) d 3.37–
3.50 ppm (m, 2H), 3.96–4.05 (m, 1H), 4.32–4.43 (m, 2H), 7.45–
7 . 5 4( m ,3 H ) ,7 . 7 4 – 7 . 8 0( m ,2 H ) ,8 . 3 9( s ,1 H ) .
13C NMR
(100 MHz, DMSO) d 51.17 ppm, 63.61, 69.95, 79.57, 94.67,
99.82, 120.94, 127.55, 128.67, 129.82, 132.09, 149.35, 151.66,
152.99. Anal. Calcd for C16H16ClN5O2 (345.10): C, 55.58; H,
4 . 6 6 ;N ,2 0 . 2 5 .F o u n d :C ,5 5 . 6 5 ;H ,4 . 7 0 ;N ,2 0 . 2 8 .
Biology
Yeast strains and plasmids. Strains used: W303 (MATa
ade2-1 ura3-1 leu2-3,112 trp1-1 his3-11 can1-100 GAL SUC2) and its
derivatives, W303 hog1-as strain (MATa ade2-1 ura3-1 leu2-3,112
trp1-1 his3-11 can1-100 GAL SUC2 hog1-as) and W303 pbs2-as strain
(MATa ade2-1 ura3-1 leu2-3,112 trp1-1 his3-11 can1-100 GAL SUC2
pbs2::URA pbs2-as:TRP). The pRS426TEG1 (pTEF1-GST, URA3
+,
2 mm) vector was a gift from M. Takekawa. The pRS426TEG1-
hog1as was created by cloning the hog1 mutant ORF plus 500 bp
upstream and downstream, into pRS426TEG1 empty plasmid. To
build the as mutant the hog1 orf was mutated by PCR in the amino
acid 100 (T-ACG-RG-GGG- ). The pRS304-Pbs2as vector was
created by cloning the pbs2 mutant ORF plus 500 bp upstream
and downstream, into pRS304 empty plasmid. To build the as
mutant the pbs2 orf was mutated by PCR in the amino acid 435
(M-ATG-RA-GCG-). ssk2DN, pbs2
EE, HOG1, PBS2, pbs2-as and
SIC1 ORFs were cloned into pGEX-4T1 (Pharmacia) to obtain
GST fusion proteins. The STL1::LacZ reporter construct PEN05
was generated by cloning the STL1 promoter (base pairs 2824 to
+4) by PCR into YIp358R (CEN URA3).
Expression and purification of epitope-tagged pro-
teins. GST fusion proteins were expressed in E.coli DH5a,a n d
purified using glutathione-Sepharose beads (Pharmacia) in buffer B as
described [28]. The beads were washed extensively with buffer B and
finally proteins were eluted with kinase buffer plus glutathione
(50 mM Tris-HCl pH 8.0, 2 mM DTT, 10 mM glutathione). GST-
Hog1as was expressed in S. cerevisiae and purified using glutathione-
Sepharose beads (Pharmacia) in buffer B, as described above.
In vitro phosphorylation experiments. One microgram of
recombinant GST-Hog1 or GST-Pbs2 was activated by
phosphorylation using 0.5 mg of either GST-Pbs2
EE or GST-
Ssk2DN in the presence of kinase buffer and ATP as described [28].
After 20 min at 30uC, substrate was added (GST-Sic1 for Hog1 or
GST-Hog1 for Pbs2) to the previous mixture together with [c-
32P]-
ATP (for wt kinases) or [c-
32P]-phenethyl-ATP (for as kinases)
(5 mCi). The mixture was then incubated for 10 min at 30uC, and
the reactions were terminated by the addition of 56SDS loading
buffer. Labeled proteins were resolved by SDS-PAGE and detected
by autoradiography. Inhibitors were added to the first mixture at
the indicated concentration. The assessment of the IC50 was
performed by the quantification of phosphorylated substrates (Sic1
or Hog1) by using Quantity One software (BioRad).
b-galactosidase assays. Exponentially growing cells
(OD660=0.8) were incubated with the specified inhibitor
previous to be subjected to osmotic stress (0.4 M NaCl for
30 min). Cells were permeabilized by ethanol-toluene treatment,
and b-galactosidase was measured as described [29]. Results are
presented as mean values obtained from two independent
transformants measured at least in triplicate.
Cytometry analyses. For flow cytometry analyses, cells were
fixed in ethanol, treated with RNAse A, stained with propidium
iodide and analysed in a FACScan flow cytometer (Becton
Dickinson) in the FL3 channel. A total of 10000 cells were
analysed for each time point.
Chemical Genetic Profiling. Yeast profiling was performed
exactly as described by Ericson et al [30]. Gene set enrichment was
carried out on the non-essential yeast genes in the chemogenomic
profile using GSEA [31] and the results were visualized as a
network using the enrichment map plugin [32] for cytoscape [33].
Modeling
MolIDE/ICM modeling. The initial model of Hog1 was
created using the standard procedure built into the program ICM,
based on the structure of human p38 (pdb code 1p38) [34]. The
model was refined by regularization, which imposes ideal
geometry onto the model, followed by geometry optimization by
Monte Carlo simulated annealing in torsion space. (ICM manual,
Molsoft, CA) Ligands were manually docked into the site and
geometry optimized by minimization and Monte Carlo
conformation sampling. In the early phase of optimization,
ligand atoms were tethered to their original positions using
harmonic potentials that were gradually decreased in strength.
Eight additional wild-type and mutant Hog1 models were
created based on four structure templates (pdb codes 1cm8, 1m7q,
1p38 and 3erk) to provide a better understanding of the
orthogonal ligands’ affinities. Template selection was carried out
using the MolIDE program [35], which is an interface to programs
that performs psi-blast searches against the nr database and stores
the generated alignment profiles, searches the pdb sequences using
the profiles, constructs a backbone model for aligned residues,
adds and geometry optimizes side-chains and builds loops.
Pairwise sequence alignments were manually edited before model
building.
Kinase models built by MolIDE were regularized by ICM
before docking and quality assessment. The local quality of protein
models was checked using ICM’s calcEnergyStrain, which
identifies bad regions by reporting the relative energy of each
residue.
Docking of a small library of the designed and known kinase
inhibitors was performed using the standard protocol in ICM (data
not shown), and the representative mutant and wild-type Hog1
models were manually chosen based on the accuracy of ligand
docking poses.
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